 |
 Video: What is a Stock Split?
|
|
|
| UroGen Pharma is a biotechnology company focused on developing and commercializing solutions that treat urothelial and specialty cancers. Co. has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based technology that has the potential to improve therapeutic profiles of existing drugs. Co.'s Jelmyto® (mitomycin) for pyelocalyceal solution, and its UGN-102 (mitomycin) for intravesical solution, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer, respectively. According to our UroGen Pharma stock split history records, UroGen Pharma has had 0 splits. | |
|
UroGen Pharma (URGN) has 0 splits in our UroGen Pharma stock split history database.
Looking at the UroGen Pharma stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into UroGen Pharma shares, starting with a $10,000 purchase of URGN, presented on a split-history-adjusted basis factoring in the complete UroGen Pharma stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
05/05/2017 |
|
| End date: |
09/22/2023 |
|
| Start price/share: |
$14.00 |
|
| End price/share: |
$15.69 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
12.07% |
|
| Average Annual Total Return: |
1.80% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$11,206.75 |
|
| Years: |
6.39 |
|
|
|
|
|
